Dr Reddy's Shares Soar 5% as Q3 Results Beat Expectations, Brokerages Turn Bullish

• Dr Reddy's Laboratories (DRL) shares surged over 5% after better-than-expected Q3 results, despite a 14% profit decrease, revenue increased by over 4%.
• The company's margin figures also surpassed anticipations, leading to a strong rally in its share price.
• DRL management projects double-digit growth in non-US markets and 15-16% growth in the Indian business.
• Semaglutide launch is anticipated in Canada by May 2026 and in India by March, with plans for launch in 80 markets globally.
• Brokerages like HSBC issued a 'BUY' call with a target of Rs 1435, citing strong Indian sales, while CLSA upgraded to 'Hold' with a target of Rs 1210.

Why It Matters: Dr Reddy's shares rallied over 5% due to strong Q3 results and bullish brokerage outlooks.